Puma Biotechnology (PBYI)

$2.86 -0.02 (-0.69%)
Market Cap 141.89M
Revenue (ttm) 230.47M
Net Income (ttm) 30.28M
EPS (ttm) N/A
PE Ratio 4.85
Forward PE 7.16
Profit Margin 13.14%
Debt to Equity Ratio 0.73
Volume 224,000
Avg Vol 393,734
Day's Range N/A - N/A
Shares Out 49.61M
Stochastic %K 67%
Beta 1.34
Analysts Hold
Price Target $4.33

Latest News on PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2025, 5:15 PM EDT - 18 days ago

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma SE: Undervalued With Tailwinds Ahead

Mar 31, 2025, 4:53 AM EDT - 21 days ago

Puma SE: Undervalued With Tailwinds Ahead

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Mar 26, 2025, 9:00 AM EDT - 25 days ago

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

PUMA SE: This Is The Right Time To Buy

Mar 21, 2025, 7:46 AM EDT - 4 weeks ago

PUMA SE: This Is The Right Time To Buy

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Mar 5, 2025, 5:30 PM EST - 6 weeks ago

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:02 PM EST - 7 weeks ago

Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 4:05 PM EST - 7 weeks ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference

Feb 26, 2025, 4:15 PM EST - 7 weeks ago

Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:15 PM EST - 2 months ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Dec 23, 2024, 9:01 AM EST - 4 months ago

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Dec 16, 2024, 11:36 AM EST - 4 months ago

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Nov 20, 2024, 8:57 AM EST - 5 months ago

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 11:09 PM EST - 5 months ago

Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript

Puma Biotechnology Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:05 PM EST - 5 months ago

Puma Biotechnology Reports Third Quarter 2024 Financial Results

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Oct 24, 2024, 4:07 PM EDT - 6 months ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:15 PM EDT - 8 months ago

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:54 PM EDT - 9 months ago

Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript

Puma Biotechnology Reports Second Quarter Financial Results

Aug 1, 2024, 4:05 PM EDT - 9 months ago

Puma Biotechnology Reports Second Quarter Financial Results

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Jul 18, 2024, 4:10 PM EDT - 9 months ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Jun 3, 2024, 2:33 PM EDT - 11 months ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

Jun 2, 2024, 10:01 AM EDT - 11 months ago

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

Puma Biotechnology to Join Russell 3000 Index

May 28, 2024, 9:00 AM EDT - 11 months ago

Puma Biotechnology to Join Russell 3000 Index

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 23, 2024, 5:15 PM EDT - 11 months ago

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript

May 2, 2024, 10:11 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript

Puma Biotechnology Reports First Quarter Financial Results

May 2, 2024, 4:05 PM EDT - 1 year ago

Puma Biotechnology Reports First Quarter Financial Results

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Apr 18, 2024, 4:15 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Mar 20, 2024, 8:30 AM EDT - 1 year ago

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 8:39 PM EST - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 4:05 PM EST - 1 year ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

Feb 22, 2024, 4:10 PM EST - 1 year ago

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 4:10 PM EST - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Feb 13, 2024, 8:30 AM EST - 1 year ago

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 4:07 PM EST - 1 year ago

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Puma Biotechnology: Profitable, Troubled, But Worth A Good Look

Dec 14, 2023, 1:41 AM EST - 1 year ago

Puma Biotechnology: Profitable, Troubled, But Worth A Good Look

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Dec 11, 2023, 8:30 AM EST - 1 year ago

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology, Inc. (PBYI) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 10:21 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q3 2023 Earnings Call Transcript

Puma Biotechnology Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Puma Biotechnology Reports Third Quarter 2023 Financial Results

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

Oct 19, 2023, 4:14 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Oct 14, 2023, 12:30 PM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

Sep 21, 2023, 4:10 PM EDT - 1 year ago

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 4:07 PM EDT - 1 year ago

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

Aug 8, 2023, 8:30 AM EDT - 1 year ago

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

Puma Biotechnology, Inc. (PBYI) Q2 2023 Earnings Call Transcript

Aug 3, 2023, 10:57 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q2 2023 Earnings Call Transcript

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

Jul 20, 2023, 4:15 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Jun 4, 2023, 9:00 AM EDT - 2 years ago

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Puma Biotechnology, Inc. (PBYI) Q1 2023 Earnings Call Transcript

May 4, 2023, 10:54 PM EDT - 2 years ago

Puma Biotechnology, Inc. (PBYI) Q1 2023 Earnings Call Transcript

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

Apr 20, 2023, 4:15 PM EDT - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

Mar 14, 2023, 8:30 AM EDT - 2 years ago

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

Puma Biotechnology, Inc. (PBYI) Q4 2022 Earnings Call Transcript

Mar 2, 2023, 6:29 PM EST - 2 years ago

Puma Biotechnology, Inc. (PBYI) Q4 2022 Earnings Call Transcript